VERTEX PHARMACEUTICALS INC / MA Long-Lived Assets
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Long-Lived Assets of $3.08 billion as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2026-02-13
- 2025-12-31: Long-Lived Assets $3.08B.
- 2024-12-31: Long-Lived Assets $2.58B.
- 2023-12-31: Long-Lived Assets $1.45B.
- 2022-12-31: Long-Lived Assets $1.46B.
| Period end | Long-Lived Assets | Long-Lived Assets as first filed |
|---|---|---|
| 2025-12-31 | $3.08B 10-K · filed 2026-02-13 | |
| 2024-12-31 | $2.58B 10-K · filed 2026-02-13 | |
| 2023-12-31 | $1.45B 10-K · filed 2025-02-13 | |
| 2022-12-31 | $1.46B 10-K · filed 2024-02-15 | |
| 2021-12-31 | $1.42B 10-K · filed 2023-02-10 | |
| 2020-12-31 | $1.28B 10-K · filed 2022-02-09 | $1.28B 10-K · filed 2021-02-11 |
| 2019-12-31 | $833.28M 10-K · filed 2021-02-11 | |
| 2018-12-31 | $812.00M 10-K · filed 2020-02-13 | |
| 2017-12-31 | $789.44M 10-K · filed 2019-02-13 | |
| 2016-12-31 | $698.36M 10-K · filed 2018-02-15 | |
| 2015-12-31 | $697.72M 10-K · filed 2017-02-23 | |
| 2014-12-31 | $715.81M 10-K · filed 2016-02-16 | |
| 2013-12-31 | $696.91M 10-K · filed 2015-02-13 | |
| 2012-12-31 | $433.61M 10-K · filed 2014-02-11 | |
| 2011-12-31 | $133.18M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |